A framework for identification of actionable cancer genome dependencies in small cell lung cancer. - Wikidata - awgldk - TriplyDB

A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

http://www.wikidata.org/entity/Q36342432

about

Targeted drugs in small-cell lung cancer Small cell lung cancer (SCLC): no treatment advances in recent years Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer Origins, genetic landscape, and emerging therapies of small cell lung cancer Genomic profiling of small-cell lung cancer: the era of targeted therapies Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer Molecular pathways and therapeutic targets in lung cancer Systems biology approaches to develop innovative strategies for lung cancer therapy.Small cell lung cancer: where do we go from here?Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer.Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma Small cell lung cancer: will recent progress lead to improved outcomes?Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Progress in the management of limited-stage small cell lung cancer.HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Advances in pharmacotherapy of small cell lung cancer.The kinome 'at large' in cancer.Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.The MYCN Protein in Health and Disease.Left behind? Drug discovery in extensive-stage small-cell lung cancer.Family matters: How MYC family oncogenes impact small cell lung cancer.Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Small-cell lung cancer: what we know, what we need to know and the path forward.Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer.Biology and evolution of poorly differentiated neuroendocrine tumors.The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.

P2860

Q26767017-888ED293-9550-4769-9DA1-A2CD494D5559 Q26767020-61379A0B-CEC5-4253-8389-DF1A4A497865 Q26784060-A4906663-023E-419D-9319-124A282F4FB7 Q26798218-5007D716-D032-41C2-A2CE-921C79802987 Q26826915-BB3D6326-DC00-43FE-B572-93AFEEECF89D Q28542859-644AEBA1-AFEF-4348-ABB1-C77DCDD8E96A Q28818608-B4B998F1-F157-42E4-AED5-4BE5FFA4C037 Q33643375-E8702D13-F3FC-4962-96CC-19CB8A8BE311 Q33688872-4CAE0D89-0E6A-47A3-BCF0-A8ADD26CADA0 Q33720233-18D0C1C0-2453-4E82-9B51-4E0E60E490C5 Q33872327-EE57B018-8314-4802-AF1B-F0DA10FE3080 Q34044287-A8AA6D9E-895D-4377-9E22-8630506F0A9C Q34134584-D2434CD0-29AA-41E1-B941-D103D46E386B Q34729370-F7C2CC1C-0595-407C-90B1-4E4323F1C5E4 Q35715821-0434B96A-3194-475B-8084-044E0DB68181 Q35819646-9A74BA16-C899-45AC-8D5B-20D074D964CC Q35836257-C2733746-E51D-4429-9549-298242FACF76 Q35895426-27A9A643-1CB1-42A2-8836-AEE01935965F Q36035933-BE4D1256-B39A-4E8C-96A2-959D403C4C2A Q36278557-89444CCD-82A1-4FC6-B11A-6170D3C74C2B Q36811784-ECEC5158-7672-4125-864C-E9C2987EA16E Q37250224-6D9325AD-CC68-406B-AD20-2D33D9C700C9 Q37327647-2D07F504-84A1-4827-86D8-167B122F5E7C Q37424084-9243E4E8-DDCB-4A0E-B3CE-AF0EE433DB64 Q37444264-FE8E8CC9-5771-4773-8F82-FEA1B814BDB3 Q37590339-63571A2E-4CA2-4B1E-A691-40AEFB7089B2 Q37626969-7AE42C46-B106-49DB-94F2-C2774996C04F Q37728631-7B147552-9024-4286-BC87-C2BB9E725252 Q38254295-C4E69915-C143-42E7-B37D-B087B7CA891F Q38715428-B854A88C-82AA-4FD4-BB6C-B255F881EF2A Q38753586-F6883F44-2ABC-4414-8575-A21E9305C12A Q39019412-A4894A2D-FE50-40CE-91B1-8248048B5B17 Q39208675-D4E43D9F-BBBE-4FD1-B2D9-E5C8F8D54D29 Q39250401-F8F86CF6-4F9C-4F06-9B21-A870D06EDD98 Q39454070-F4C00B0B-E0EF-486A-8B09-98B47D0807E8 Q47161308-25DC7E79-D393-49FD-A529-D2D3E2382595 Q47595394-7B1B245E-59CA-449F-A55C-47E47C989F41 Q47932500-CBB37461-2748-4B5A-99D9-61256234A725 Q48320507-B4AF6EF0-52F1-4995-B59A-0315BA447C30 Q50452810-ED344240-00F8-447F-ACD2-DCDB667DE02A

P2860

A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

http://www.wikidata.org/entity/Q36342432

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

A framework for identification ...... ies in small cell lung cancer.

@ast

A framework for identification ...... ies in small cell lung cancer.

@en

type

label

A framework for identification ...... ies in small cell lung cancer.

@ast

A framework for identification ...... ies in small cell lung cancer.

@en

prefLabel

A framework for identification ...... ies in small cell lung cancer.

@ast

A framework for identification ...... ies in small cell lung cancer.

@en

P1433

Q36342432-15353A94-9671-4A57-BD61-EB3916DB0CFB

P1476

Q36342432-0A0D4D35-0450-42BB-8612-0B40F43CD1EC

P2093

Q36342432-118D3F41-082A-4AE6-B432-9DBAD4DA848E

Q36342432-2AEC62EE-58E8-4CB5-8923-7C118294A53E

Q36342432-302E6C54-FA9F-4E8A-89F4-107FE165E15E

Q36342432-340C250B-22F5-45F4-B0EB-FB408AAC55DC

Q36342432-4A9D0B7C-2CBD-40B9-B0C1-F5498DEFB272

Q36342432-685DB688-4638-4087-B841-8B97958DBDC0

Q36342432-7FC90816-4E0C-4E9D-83FE-0D27C697EC03

Q36342432-83C83023-69B5-4303-995B-65CDA79E347C

Q36342432-856B732B-E3A7-4C57-AFDD-0C506D81C711

Q36342432-93863C35-15A4-4F61-BD8C-5FEE4F6D0B0A

P2860

Q36342432-02A921B0-E330-4F5B-BB74-A1908E61CF69

Q36342432-0BE8C4C0-4C95-404F-93D6-D1B726D531E1

Q36342432-10F58849-7E0D-419B-81A6-A8BE4DF5CCBA

Q36342432-126127FF-1CBF-4DA4-9337-C50C75CCCCB1

Q36342432-1A9BB905-5739-4C25-A458-2FC4929C38B6

Q36342432-1F6E7A3D-F256-4008-95B1-AB9E5931D09D

Q36342432-221BFA16-38A1-497E-AAB9-592A28C38551

Q36342432-22702FE8-1B0F-4CCB-A973-BF79A890F391

Q36342432-2334589C-5CAF-4536-9230-3847CD0DE550

Q36342432-2BEB8A97-7840-4291-91DE-EF3A68640D26

P304

Q36342432-624AE482-3D13-4B68-BEC1-5182E4E13260

P31

Q36342432-C05624E5-B0E2-4F67-890D-1CD968F5B065

P356

Q36342432-66116D33-668E-477C-A494-565A1A29CDCB

P407

Q36342432-BCDD0B78-D169-4741-AB08-3D150B4586DC

P433

Q36342432-35610765-178A-4F8F-BB62-4EF11ECC088F

P478

Q36342432-19304EC5-3540-4AC8-AEA5-22FC49A16BE4

P50

Q36342432-2C55E10F-B6AB-4461-91AE-4C6E10D599A1

Q36342432-8B1277DB-3B8C-47C7-9C22-04B1F5EB0DC5

Q36342432-E4937488-82D8-435B-9A80-FD69B9672ABD

Q36342432-EBE3233F-262B-4AC3-98AF-31A27C5E6E12

P577

Q36342432-84472FFF-6AAA-4F2E-AED9-A65528CE4D34

P5875

Q36342432-B15F5731-8A3D-40E1-A567-CCE8DAA7CA05

P698

Q36342432-E52AC93B-2F6E-4319-866F-ED26BD9EC842

P932

Q36342432-192A4F9D-CF0E-4C17-83F0-D5A541F954F8

P356

PNAS.1207310109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A framework for identification ...... ies in small cell lung cancer.

@en

P2093

André Richters

http://www.w3.org/2001/XMLSchema#string

Christian Müller

http://www.w3.org/2001/XMLSchema#string

Danila Seidel

http://www.w3.org/2001/XMLSchema#string

Felix Dietlein

http://www.w3.org/2001/XMLSchema#string

Florian Malchers

http://www.w3.org/2001/XMLSchema#string

Hyatt Balke-Want

http://www.w3.org/2001/XMLSchema#string

Jakob Schöttle

http://www.w3.org/2001/XMLSchema#string

Johannes M Heuckmann

http://www.w3.org/2001/XMLSchema#string

Lukas C Heukamp

http://www.w3.org/2001/XMLSchema#string

Martin L Sos

http://www.w3.org/2001/XMLSchema#string

P2860

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

A new screening assay for allosteric inhibitors of cSrc

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

P304

17034-17039

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1207310109

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Herbert Waldmann

Andrey P. Antonchick

P577

2012-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232011766

http://www.w3.org/2001/XMLSchema#string

P698

23035247

http://www.w3.org/2001/XMLSchema#string

P932

3479457

http://www.w3.org/2001/XMLSchema#string